000 03217nam a22005055i 4500
001 978-94-007-1706-0
003 DE-He213
005 20140220083338.0
007 cr nn 008mamaa
008 110907s2012 ne | s |||| 0|eng d
020 _a9789400717060
_9978-94-007-1706-0
024 7 _a10.1007/978-94-007-1706-0
_2doi
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
100 1 _aHayat, M.A.
_eeditor.
245 1 0 _aTumors of the Central Nervous System, Volume 4
_h[electronic resource] :
_bBrain Tumors (Part 2) /
_cedited by M.A. Hayat.
264 1 _aDordrecht :
_bSpringer Netherlands,
_c2012.
300 _aXXVI, 386 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aTumors of the Central Nervous System ;
_v4
520 _aThis volume mainly contains information on the diagnosis, therapy, and prognosis of brain tumors. Insights on the understanding of molecular pathways involved in tumor biology are explained, which should lead to the development of effective drugs. Information on pathways (e.g., hedgehog) facilitates targeted therapies in cancer. Tumor models are also presented, which utilize expression data, pathway sensitivity, and genetic abnormalities, representing targets in cancer. For example, rat model of malignant brain tumors using implantation of doxorubicin with drug eluting beads for delivery is explained. The future of pathway-driven therapies for tumors is summarized. The importance of personalizing cancer care is emphasized. The need for supportive measures for survivors of brain cancer is pointed out, so is the quality of life monitoring. The need of rehabilitation therapy for patients with primary and metastatic brain tumors is also emphasized. Role of MicroRNA in distinguishing primary tumors from metastatic primary tumors is discussed. Advantages and limitations of chemotherapy (e.g., temozolomide and doxorubicin) are discussed. The complexity of tumor to tumor transfer is explained; examples discussed are: brain metastases from breast cancer and brain metastases fro non-small cell lung carcinoma. Identification and characterization of biomarkers, including those for metastatic brain tumors, are presented. Genomic analysis for identifying clinically relevant subtypes of glioblastoma is included. A large number of imaging modalities are detailed to study progression and invasion of gliomas.
650 0 _aMedicine.
650 0 _aOncology.
650 0 _aRadiology, Medical.
650 0 _aNeurosurgery.
650 0 _aPathology.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aNeuroradiology.
650 2 4 _aNeurosurgery.
650 2 4 _aOncology.
650 2 4 _aPathology.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9789400717053
830 0 _aTumors of the Central Nervous System ;
_v4
856 4 0 _uhttp://dx.doi.org/10.1007/978-94-007-1706-0
912 _aZDB-2-SBL
999 _c104315
_d104315